[go: up one dir, main page]

ATE551361T1 - Mutante des granulozytenkoloniestimulierenden faktors (g-csf) und chemisch konjugiertes polypeptid davon - Google Patents

Mutante des granulozytenkoloniestimulierenden faktors (g-csf) und chemisch konjugiertes polypeptid davon

Info

Publication number
ATE551361T1
ATE551361T1 AT06783354T AT06783354T ATE551361T1 AT E551361 T1 ATE551361 T1 AT E551361T1 AT 06783354 T AT06783354 T AT 06783354T AT 06783354 T AT06783354 T AT 06783354T AT E551361 T1 ATE551361 T1 AT E551361T1
Authority
AT
Austria
Prior art keywords
csf
residue
mutant
cysteine
stimulating factor
Prior art date
Application number
AT06783354T
Other languages
English (en)
Inventor
Kwan-Yub Kang
Jeong-Woon Hong
Original Assignee
Mogam Biotech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Biotech Res Inst filed Critical Mogam Biotech Res Inst
Application granted granted Critical
Publication of ATE551361T1 publication Critical patent/ATE551361T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06783354T 2005-07-20 2006-07-19 Mutante des granulozytenkoloniestimulierenden faktors (g-csf) und chemisch konjugiertes polypeptid davon ATE551361T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020050065746A KR100735784B1 (ko) 2005-07-20 2005-07-20 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
PCT/KR2006/002841 WO2007011166A1 (en) 2005-07-20 2006-07-19 Mutant of granulocyte-colony stimulating factor(g-csf) and chemically conjugated polypeptide thereof

Publications (1)

Publication Number Publication Date
ATE551361T1 true ATE551361T1 (de) 2012-04-15

Family

ID=37669016

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06783354T ATE551361T1 (de) 2005-07-20 2006-07-19 Mutante des granulozytenkoloniestimulierenden faktors (g-csf) und chemisch konjugiertes polypeptid davon

Country Status (8)

Country Link
US (1) US8841426B2 (de)
EP (2) EP1919945B1 (de)
JP (1) JP4782834B2 (de)
KR (1) KR100735784B1 (de)
CN (2) CN101213208A (de)
AT (1) ATE551361T1 (de)
ES (2) ES2428863T3 (de)
WO (1) WO2007011166A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0605684D0 (en) * 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
WO2008147534A1 (en) * 2007-05-22 2008-12-04 Maxygen Holdings Ltd. Method for the treatment of neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant
WO2009116524A1 (ja) * 2008-03-17 2009-09-24 独立行政法人理化学研究所 改変タンパク質
EP2274325A4 (de) * 2008-05-13 2011-05-25 Nora Therapeutics Inc Analoga von humanem g-csf und verfahren zur herstellung und anwendung davon
EP2318029B1 (de) * 2008-07-23 2017-11-01 Ambrx, Inc. Modifizierte bovine g-csf-polypeptide und ihre verwendung
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
EP3694535B1 (de) * 2017-10-11 2025-11-26 Elanco US Inc. Varianten des porzinen g-csf und ihre verwendungen
JP2021509805A (ja) * 2017-12-27 2021-04-08 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 顆粒球コロニー刺激因子活性を示すポリペプチド
CN116334057B (zh) * 2022-08-16 2024-07-19 北京理工大学 一种利用聚乙二醇马来酰亚胺衍生物构建的酶组装体及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0347041A3 (de) * 1988-05-13 1990-11-22 Amgen Inc. Zusammensetzungen und Verfahren zur Behandlung oder Verhütung von Infektionen bei Tieren
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3708151B2 (ja) * 1994-12-15 2005-10-19 協和醗酵工業株式会社 Peg化したヒト顆粒球コロニー刺激因子の定量法
US6066318A (en) * 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
KR100230579B1 (ko) 1997-04-23 1999-12-01 허영섭 과립구 콜로니 자극인자를 발현하는 재조합 미생물 및 그로부터 전기 재조합 단백질의 제조방법
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
KR100260350B1 (ko) * 1998-02-09 2000-07-01 허영섭 과립구 콜로니 자극인자의 유도체 단백질을 생산하는 재조합 미생물 및 그로부터 전기 재조합 단백질의 제조방법
NZ513077A (en) 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
EP2133098A1 (de) 2000-01-10 2009-12-16 Maxygen Holdings Ltd G-CSF-Konjugate
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
AU2001238595A1 (en) * 2000-02-22 2001-09-03 Shearwater Corporation N-maleimidyl polymer derivatives
US7557195B2 (en) * 2002-03-20 2009-07-07 Biopolymed, Inc. Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF
JP4412461B2 (ja) * 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
KR20040083268A (ko) * 2003-03-21 2004-10-01 한미약품 주식회사 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법

Also Published As

Publication number Publication date
KR20070010817A (ko) 2007-01-24
EP1919945A1 (de) 2008-05-14
JP2009501789A (ja) 2009-01-22
US8841426B2 (en) 2014-09-23
EP2174951A2 (de) 2010-04-14
KR100735784B1 (ko) 2007-07-06
US20080200657A1 (en) 2008-08-21
CN102153643B (zh) 2012-12-12
ES2381256T3 (es) 2012-05-24
EP2174951A3 (de) 2010-07-07
CN101213208A (zh) 2008-07-02
JP4782834B2 (ja) 2011-09-28
ES2428863T3 (es) 2013-11-12
EP1919945A4 (de) 2009-02-18
CN102153643A (zh) 2011-08-17
WO2007011166A1 (en) 2007-01-25
EP1919945B1 (de) 2012-03-28
EP2174951B1 (de) 2013-09-11

Similar Documents

Publication Publication Date Title
ZA200800533B (en) Glycosylated IL-7, preparation and uses
EP1778842B8 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
ATE417595T1 (de) Keratin-bindende polypeptide
DE60329201D1 (de) Substituierte wt1-peptide
DK1877435T3 (da) Glucagon-lignende peptid 2 (GLP-2)-analoger
JP2013543497A5 (de)
ATE551361T1 (de) Mutante des granulozytenkoloniestimulierenden faktors (g-csf) und chemisch konjugiertes polypeptid davon
DK1196444T3 (da) Exendin-4-konjugater og deres medicinske anvendelighed
CY1106723T1 (el) Ν-τελικα μονοπεγυλιωμενα συζευγματα ανθρωπινης αυξητικης ορμονης, διεργασιες για την παρασκευη τους και μεθοδοι χρησης αυτων
ES2689781T3 (es) Angiotensina en el tratamiento de afecciones cerebrales
NO20023315D0 (no) G-CSF konjugater
MX2009012675A (es) Tensioactivos reconstituidos que tienen propiedades mejoradas.
CN102143970A (zh) α-促黑素细胞激素的肽类似物
TW200631592A (en) Soluble, stable insulin-containing formulations
IL195831A0 (en) Sparc-derived tumor rejection antigenic peptides and medicaments comprising the same
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
ATE412671T1 (de) Modifizierter faktor viii
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
ATE538806T1 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
RU2002115633A (ru) Конъюгаты интерферона
KR102166543B1 (ko) 켈로이드 억제용 조성물 및 그 억제 방법
RU2005102040A (ru) Искусственная биокожа "ростоши"
CY1114720T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια